IADR Abstract Archives

Anabolic Conjugated Drugs with Resorbable Monetite for Enhanced Bone Regeneration

Objectives: Monetite (dicalcium phosphate anhydrous) can be used for bone grafting procedures including alveolar bone augmentation; however, it lacks osteoinduction. A variety of molecules can be incorporated within the monetite matrix that can be released locally during graft degradation to promote bone regeneration. We developed two novel bone anabolic conjugated drugs, known as C3 and C6, consisting of a potent bone activating EP4 receptor agonist and an inactive bisphosphonate. The aim was to investigate whether incorporating these conjugates in the matrix of monetite granules can enhance bone regeneration in critical-sized bone defects using a rat mandibular model.
Methods: Critical-sized bone defects (4.3mm diameter, through and through) were created bilaterally in the mandible of 24 Sprague Dawley rats and were then packed with either monetite control, monetite with C3 or monetite with C6 (n=8 defects/group per time-point). After 2 and 4 weeks, post-mortem samples were analyzed using microcomputed tomography, histology and Backscattered electron microscopy to calculate the percentages of bone formation and remaining graft material. One-way ANOVA with post-hoc Tukey test was used to test for statistical significance (set at P < 0.05).
Results: At 2 and 4 weeks, monetite granules with the C3 and C6 conjugated drugs demonstrated higher bone formation percentage than the control group, while the monetite C6 group had the highest bone formation percentage at 4 weeks (P < 0.05).There were no significant differences in the percentage of remaining graft material between the different group at 2 weeks or 4 weeks.
Conclusions: Monetite granules containing the novel C3 and C6 anabolic conjugate resulted in a greater rate of bone formation when compared to monetite granules devoid of conjugates. Incorporating these anabolic conjugates within the degradable matrix of monetite present a promising bone graft alternative for bone regeneration and repair for oral and maxillofacial application including regeneration of alveolar bone defects.
IADR/AADR/CADR General Session
2020 IADR/AADR/CADR General Session (Washington, D.C., USA)
Washington, D.C., USA
2020
0091
Dental Materials 5: Biocompatibility, Bioengineering and Biologic Effects of Materials
  • Abdallah, Mohamed-nur  ( University of Toronto , Toronto , Ontario , Canada ;  Lunenfeld-Tanenbaum Research Institute , Toronto , Ontario , Canada )
  • Sheikh, Zeeshan  ( University of Toronto , Toronto , Ontario , Canada ;  Lunenfeld-Tanenbaum Research Institute , Toronto , Ontario , Canada ;  University of Toronto , Toronto , Ontario , Canada ;  Dalhousie University , Halifax , Nova Scotia , Canada )
  • Al-jaf, Faik  ( University of Toronto , Toronto , Ontario , Canada )
  • Chen, Gang  ( Simon Fraser University , Burnaby , British Columbia , Canada )
  • Hamdan, Nader  ( Dalhousie University , Halifax , Nova Scotia , Canada )
  • Young, Robert  ( Simon Fraser University , Burnaby , British Columbia , Canada )
  • Glogauer, Michael  ( University of Toronto , Toronto , Ontario , Canada ;  Princess Margaret Cancer Centre , Toronto , Ontario , Canada )
  • Grynpas, Marc  ( University of Toronto , Toronto , Ontario , Canada ;  Lunenfeld-Tanenbaum Research Institute , Toronto , Ontario , Canada ;  University of Toronto , Toronto , Ontario , Canada ;  University of Toronto , Toronto , Ontario , Canada )
  • MITACS Accelerate Grant, Network for Canadian Oral Health Research, and the American Association of Orthodontists Foundation
    Dr. Gang reports financial support from BC Leadership Endowment Fund during the conduct of the study. In addition, Gang Chen has a patent US Patent #10400000 (Sept 3, 2019) and is an inventor of the patent. Dr. Young reports other from BC Leadership Endow
    Oral Session
    Keynote Address; New Horizons in Bone Tissue Regeneration